Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-05-29

Clinical Trial Update: SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating SPD489 at low and high doses added to stable antipsychotic regimens in adults with negative symptoms of schizophrenia; study terminated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SPD489

Snippet

Sponsor: Shire | Conditions: Schizophrenia | Phase 3 | Status: TERMINATED | Results posted: 2014-05-29